A

Alberta DermaSurgery Centre | Edmonton, AB

Research site
(Unclaimed)
Location
United Health Centres – 3rd floor 7609 109 St NW, Suite 300, Edmonton, Alberta, Canada
Site insights

Top conditions

Dermatitis (11 trials)

Eczema (11 trials)

Atopic Dermatitis (11 trials)

Psoriasis (8 trials)

Hidradenitis (3 trials)

Top treatments

Upadacitinib
Lebrikizumab
Dupilumab
RIST4721
Daxdilimab
Deucravacitinib
JNJ-77242113
LY3009104
Abrocitinib
AGN-151586

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 25
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Eltrekibart
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Enrolling
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo
Locations recently updated

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Topical corticosteroid
Drug: Placebo

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moder...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to <18 ye...

Enrolling
Plaque Psoriasis
Other: Placebo matching deucravacitinib
Drug: Deucravacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center sca...

Enrolling
Atrophic Acne Scars
Other: Saline Control
Device: ELAPR002f Injectable Gel

This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in...

Enrolling
Atopic Dermatitis
Other: Placebo
Biological: NM26-2198

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 2
Drug: Placebo matching Spesolimab Formulation 1

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Enrolling
Discoid Lupus Erythematosus
Drug: Daxdilimab
Drug: Placebo/Daxdilimab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Guselkumab
Drug: Placebo
Locations recently updated

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Trial sponsors

AbbVie logo

AbbVie (7 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems